Skip to content
Clinical Trials – home

Enoxaparin Sodium: A Comprehensive Guide for Patients

17 / 22
trials open to patients / all trials
24+
Countries

In short

This article explores the use of Enoxaparin Sodium, a widely used low-molecular-weight heparin, in various clinical trials. These studies aim to evaluate the drug's efficacy, safety, and bioequivalence compared to other formulations or similar medications. Enoxaparin Sodium is commonly used for preventing and treating blood clots, making it a crucial medication in managing conditions like deep vein thrombosis and pulmonary embolism.

At a glance

Primary Uses
Prevention and treatment of blood clots, including deep vein thrombosis and pulmonary embolism
Administration
Subcutaneous injection, with doses ranging from 30 mg to 100 mg
Key Outcome Measures
Anti-Factor Xa activity, Anti-Factor IIa activity, Tissue Factor Pathway Inhibitor levels, incidence of thrombotic events
Safety Considerations
Bleeding risk, injection site reactions, potential for heparin-induced thrombocytopenia
Comparison Methods
Bioequivalence studies measuring pharmacodynamic parameters like Amax and AUEC
Clinical Trial Designs
Randomized, cross-over studies comparing different formulations or comparing to standard treatments
Patient Populations
Healthy volunteers for bioequivalence studies; patients with or at risk of thrombotic events for efficacy studies

What is Enoxaparin Sodium?

Enoxaparin Sodium is a medication that belongs to a class of drugs called low molecular weight heparins (LMWHs). It is commonly known by brand names such as Clexane, Lovenox, or Inhixa. Enoxaparin is derived from the intestinal mucosa of pigs and is used as an anticoagulant, which means it helps prevent blood clots from forming.

How Does Enoxaparin Work?

Enoxaparin works by enhancing the effect of a natural substance in your body called antithrombin III. This substance helps to prevent harmful blood clots by blocking clotting proteins in your blood. Specifically, enoxaparin inhibits two important factors in the blood clotting process: factor Xa and factor IIa (also known as thrombin). By doing this, enoxaparin helps to thin your blood and reduce the risk of dangerous clots forming in your veins or arteries.

Medical Uses of Enoxaparin

Enoxaparin is used to treat and prevent various conditions related to blood clots. Some of its main uses include:

  • Prevention of Deep Vein Thrombosis (DVT): This is a condition where blood clots form in the deep veins, usually in the legs. Enoxaparin is often used to prevent DVT in patients undergoing orthopedic surgeries such as hip or knee replacement.
  • Treatment of Venous Thromboembolism (VTE): This includes both DVT and pulmonary embolism (PE), which is when a blood clot travels to the lungs.
  • Prevention of blood clots in patients with acute illnesses: This includes patients who are bedridden due to heart failure, severe respiratory diseases, or other medical conditions that limit mobility.
  • Treatment of certain types of heart attacks: Specifically, it's used in the treatment of ST-segment elevation myocardial infarction (STEMI), a severe type of heart attack.

How is Enoxaparin Administered?

Enoxaparin is typically administered as a subcutaneous injection, which means it's injected just under the skin, usually in the abdomen area. It comes in pre-filled syringes, making it easier for patients to self-administer if necessary. Your healthcare provider will show you or your caregiver how to properly give the injection if you need to do it at home.

Dosage Information

The dosage of enoxaparin can vary depending on the condition being treated, the patient's weight, and other factors. Some common dosages include:

  • For preventing DVT after surgery: 40 mg once daily, starting 12 hours before surgery.
  • For treating DVT or PE: 1 mg per kg of body weight every 12 hours, or 1.5 mg per kg once daily.
  • For preventing blood clots in acutely ill patients: 40 mg once daily for 6 to 14 days.

Always follow your doctor's instructions regarding dosage and administration schedule.

Potential Side Effects

Like all medications, enoxaparin can cause side effects. Some of the most common include:

  • Bleeding: This can range from minor bleeding (such as nosebleeds or bleeding gums) to more serious internal bleeding.
  • Bruising or pain at the injection site.
  • Allergic reactions: These can include skin rashes or more severe symptoms.
  • Low platelet count (thrombocytopenia): This is a rare but serious side effect that requires immediate medical attention.

If you experience any unusual symptoms while taking enoxaparin, contact your healthcare provider immediately.

Current Research and Studies

Enoxaparin continues to be the subject of ongoing research to explore its effectiveness in various conditions:

  • COVID-19 Treatment: Studies are investigating the use of enoxaparin in treating severe COVID-19 cases with coagulation disorders.
  • Pediatric Use: Research is being conducted to determine safe and effective dosing of enoxaparin in children and neonates with thrombosis.
  • Bioequivalence Studies: Researchers are comparing the effectiveness of generic versions of enoxaparin to the brand-name versions to ensure they work similarly in the body.

These ongoing studies aim to expand our understanding of enoxaparin and potentially broaden its medical applications.

Questions people often ask

Conditions where Enoxaparin Sodium is being studied

Each condition opens its own overview and trial list

Trials with Enoxaparin Sodium

Recruiting trials first

See all 22 →
Quick filters
  • Participants:Adults
  • Participants:All ages
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).